Yes, there is a clinically significant drug interaction between voriconazole and estradiol patch
Co-administration of voriconazole with transdermal estradiol results in increased systemic exposure to estradiol, requiring close monitoring for estrogen-related adverse effects. 1
Mechanism of Interaction
Voriconazole is a potent inhibitor of CYP3A4 and CYP2C19 enzymes 2. While transdermal estradiol bypasses first-pass hepatic metabolism (unlike oral estrogen), it still undergoes systemic metabolism via CYP3A4 3. When voriconazole inhibits these metabolic pathways, estradiol clearance decreases, leading to elevated plasma concentrations.
Clinical Evidence
The most relevant data comes from a pharmacokinetic study examining voriconazole with oral contraceptives containing ethinyl estradiol 4:
- Ethinyl estradiol exposure increased by 61% (AUC) and 36% (Cmax) when co-administered with voriconazole
- Voriconazole exposure also increased by 46% (AUC) and 14% (Cmax) when given with the oral contraceptive
- This represents a bidirectional interaction
While this study used oral contraceptives rather than transdermal estradiol, the principle applies: voriconazole inhibits estrogen metabolism regardless of delivery route, though the magnitude may differ since transdermal formulations avoid first-pass metabolism 3.
Clinical Implications & Monitoring
Monitor for estrogen-related adverse effects:
- Breast tenderness or enlargement
- Fluid retention and edema
- Nausea
- Headaches
- Thromboembolic risk (though transdermal estradiol has lower baseline risk than oral) 3
Monitor for voriconazole-related toxicity:
- Visual disturbances
- Hepatotoxicity (transaminase elevations)
- Neurotoxicity (hallucinations, confusion)
- QT prolongation 2
Therapeutic drug monitoring (TDM) of voriconazole is strongly recommended 5:
- Target trough concentrations: 1.0-5.5 mg/L
- Levels >5.5 mg/L associated with increased toxicity risk
- The estradiol patch may elevate voriconazole levels into the toxic range
Management Recommendations
Do not avoid the combination - it is not contraindicated, but requires vigilance 1
Consider dose reduction of estradiol patch if estrogen-related adverse effects emerge (e.g., reduce from 100 µg to 50 µg or 25 µg patch) 3
Implement voriconazole TDM within 3-5 days of initiating combination therapy, then weekly until stable 5
Adjust voriconazole dose if trough levels exceed 5.5 mg/L (typically reduce by 50 mg increments) 5
Monitor liver function tests at baseline, weekly for first month, then monthly 2
Assess for QT prolongation with baseline and follow-up ECGs, especially if other QT-prolonging medications are present 2
Important Caveats
Transdermal estradiol is safer than oral estrogen in this context because it avoids first-pass hepatic metabolism, resulting in less pronounced CYP3A4 substrate load 3
Individual variability is substantial due to CYP2C19 genetic polymorphisms affecting voriconazole metabolism 6, 2. Poor metabolizers (CYP2C19 PM) will have markedly higher voriconazole levels and greater risk of toxicity
The interaction persists after discontinuation - voriconazole's inhibitory effects may continue for several days after stopping the drug 2
Contraceptive efficacy is maintained - despite increased estrogen exposure, there is no evidence of reduced contraceptive effectiveness; if anything, efficacy may be enhanced 4